Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies
- PMID: 24385514
- DOI: 10.1161/CIRCRESAHA.114.302355
Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies
Abstract
Understanding the pathophysiology of atherogenesis and the progression of atherosclerosis have been major goals of cardiovascular research during the previous decades. However, the complex molecular and cellular mechanisms underlying plaque destabilization remain largely obscure. Here, we review how lesional cells undergo cell death and how failed clearance exacerbates necrotic core formation. Advanced atherosclerotic lesions are further weakened by the pronounced local activity of matrix-degrading proteases as well as immature neovessels sprouting into the lesion. To stimulate translation of the current knowledge of molecular mechanisms of plaque destabilization into clinical studies, we further summarize available animal models of plaque destabilization. Based on the molecular mechanisms leading to plaque instability, we outline the current status of clinical and preclinical trials to induce plaque stability with a focus on induction of dead cell clearance, inhibition of protease activity, and dampening of inflammatory cell recruitment.
Keywords: atherosclerosis; efferocytosis; macrophages; necrotic core; neutrophils.
Similar articles
-
Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities.J Cardiovasc Pharmacol. 2011 Apr;57(4):447-54. doi: 10.1097/FJC.0b013e31820dc1db. J Cardiovasc Pharmacol. 2011. PMID: 21242806
-
Dead cell and debris clearance in the atherosclerotic plaque: Mechanisms and therapeutic opportunities to promote inflammation resolution.Pharmacol Res. 2021 Aug;170:105699. doi: 10.1016/j.phrs.2021.105699. Epub 2021 Jun 2. Pharmacol Res. 2021. PMID: 34087352 Review.
-
Prostaglandin E1 dose-dependently promotes stability of atherosclerotic plaque in a rabbit model.Can J Physiol Pharmacol. 2012 Feb;90(2):131-9. doi: 10.1139/y11-115. Epub 2012 Feb 6. Can J Physiol Pharmacol. 2012. PMID: 22309388
-
The walking dead: macrophage inflammation and death in atherosclerosis.Curr Opin Lipidol. 2017 Apr;28(2):91-98. doi: 10.1097/MOL.0000000000000394. Curr Opin Lipidol. 2017. PMID: 28134664 Free PMC article. Review.
-
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets.Nat Rev Cardiol. 2024 May;21(5):312-325. doi: 10.1038/s41569-023-00957-0. Epub 2024 Jan 2. Nat Rev Cardiol. 2024. PMID: 38163815 Review.
Cited by
-
The Roles of Periodontal Bacteria in Atherosclerosis.Int J Mol Sci. 2023 Aug 16;24(16):12861. doi: 10.3390/ijms241612861. Int J Mol Sci. 2023. PMID: 37629042 Free PMC article. Review.
-
Apolipoprotein Mimetic Peptide Inhibits Neutrophil-Driven Inflammatory Damage via Membrane Remodeling and Suppression of Cell Lysis.ACS Nano. 2021 Oct 26;15(10):15930-15939. doi: 10.1021/acsnano.1c03978. Epub 2021 Sep 29. ACS Nano. 2021. PMID: 34586780 Free PMC article.
-
Rosiglitazone modulates collagen deposition and metabolism in atherosclerotic plaques of fat-fed ApoE-knockout mice.Exp Ther Med. 2015 Oct;10(4):1265-1270. doi: 10.3892/etm.2015.2711. Epub 2015 Aug 25. Exp Ther Med. 2015. PMID: 26622476 Free PMC article.
-
Autophagy and Its Association with Macrophages in Clonal Hematopoiesis Leading to Atherosclerosis.Int J Mol Sci. 2025 Apr 1;26(7):3252. doi: 10.3390/ijms26073252. Int J Mol Sci. 2025. PMID: 40244103 Free PMC article. Review.
-
LncRNA SCARNA8 promotes atherosclerotic plaque instability by inhibiting macrophage efferocytosis.Epigenetics. 2025 Dec;20(1):2487317. doi: 10.1080/15592294.2025.2487317. Epub 2025 May 13. Epigenetics. 2025. PMID: 40356342 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources